PRESS RELEASE published on 02/07/2024 at 07:30, 1 year 11 months ago Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV Evotec SE expands partnership with ABL to develop and manufacture broadly neutralising antibodies against HIV, funded by NIAID. The collaboration aims to supply clinical material for ongoing global trials Evotec SE ABL Broadly Neutralising Antibodies HIV NIAID
PRESS RELEASE published on 01/22/2024 at 07:30, 2 years ago Evotec SE: Invitation to Conference Call Evotec SE is going to hold a conference call to provide a statement and a business update on January 22, 2024, featuring the Chairwoman of Evotec's Supervisory Board and Evotec's CEO. The call will cover the Company's commitment to compliance with Corporate Governance standards and transparent communication, as well as the execution of its existing strategy and recent market developments. For more details, including webcast access and conference call registration, please visit the provided links. Conference Call Business Update Evotec SE Corporate Governance Market Developments
PRESS RELEASE published on 11/08/2023 at 07:00, 2 years 2 months ago Evotec SE reports results for the first nine months 2023 and provides corporate update
PRESS RELEASE published on 11/07/2023 at 07:30, 2 years 2 months ago Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
PRESS RELEASE published on 11/01/2023 at 12:05, 2 years 2 months ago Evotec SE to announce results for the first nine months 2023 on 08 November 2023
PRESS RELEASE published on 10/05/2023 at 07:30, 2 years 3 months ago Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
PRESS RELEASE published on 09/27/2023 at 07:30, 2 years 4 months ago Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
PRESS RELEASE published on 09/26/2023 at 13:35, 2 years 4 months ago Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
PRESS RELEASE published on 08/29/2023 at 07:00, 2 years 5 months ago Evotec SE reports results for the first half-year 2023 and provides corporate updates
PRESS RELEASE published on 08/22/2023 at 14:00, 2 years 5 months ago Evotec SE reports first half-year 2023 results on 29 August 2023
Published on 01/30/2026 at 23:00, 1 hour 41 minutes ago Avidian Gold Corp. Announces Director Resignation
Published on 01/30/2026 at 22:45, 1 hour 56 minutes ago Noram Lithium Announces Fully Allocated Non-Brokered Financing
Published on 01/30/2026 at 22:30, 2 hours 11 minutes ago Alta Copper Receives Court Approval for Proposed Acquisition by Fortescue
Published on 01/30/2026 at 14:00, 10 hours 41 minutes ago CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 22:00, 2 hours 41 minutes ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 4 hours 31 minutes ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 4 hours 32 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 4 hours 34 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 17:45, 6 hours 56 minutes ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 1 day 6 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 6 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 6 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025